Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Curr Opin HIV AIDS. 2012 Jul;7(4):339-44. doi: 10.1097/COH.0b013e328354131e.
The recent major shift toward oral direct acting hepatitis C virus (HCV) treatments has the potential to revolutionize the global response to HCV. People who inject drugs (PWID) are a large key affected population who stand to benefit from these new medications.
There is a large number of new drug classes and targets with activity against HCV. Although effective for HCV treatment in monoinfection and coinfection with HIV, most direct-acting antivirals (DAAs) remain within the research pipeline, with only two having achieved regulatory approval to date. Clinical trial data are not available regarding HCV treatment for PWID with DAAs. This article reviews clinical data on HCV treatment for a number of promising compounds in HCV monoinfection and coinfection with HIV and discusses the barriers facing PWID in scale-up and roll-out of DAAs in the coming years.
DAAs have the potential to revolutionize HCV treatment. There will be significant access barriers for people who inject drugs to these new medications.
近期口服直接作用抗丙型肝炎病毒（HCV）药物的广泛应用，可能使 HCV 的全球治疗发生革命性改变。注射吸毒者（PWID）是一个受影响较大的人群，他们将从这些新药物中受益。
针对 HCV 有大量新的药物类别和靶点具有活性。虽然直接作用抗病毒药物（DAA）在 HCV 单感染和 HIV 合并感染中有效，但大多数 DAA 仍处于研究阶段，迄今为止只有两种获得监管批准。关于 DAA 治疗 PWID 的 HCV 治疗的临床试验数据尚不可用。本文综述了 HCV 单感染和 HIV 合并感染中几种有前途的化合物的 HCV 治疗的临床数据，并讨论了在未来几年中 PWID 面临的扩大 DAA 应用和推广的障碍。
DAA 有可能彻底改变 HCV 的治疗。PWID 使用这些新药物会面临重大的准入障碍。
